Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2016EBioMedicineOpen Access

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRikke HolmgaardEli Lilly (United States)DZDmitriy ZamarinIcahn School of Medicine at Mount SinaiALAlexander M. LesokhinMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Holmgaard et al. (2016) studied this question.

synapsesocial.com/papers/69d78d556cc86f5f11b8a476https://doi.org/10.1016/j.ebiom.2016.02.024
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling2012 · 450 citations
  2. 2Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017 · 15,268 citations
  3. 3Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy2014 · 58 citations
  4. 4Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease2009 · 135 citations
  5. 5KIT oncogene inhibition drives intratumoral macrophage M2 polarization2013 · 130 citations